KEAP1/NFE2L2 Pathway Signature Outperforms KEAP1/NFE2L2 Mutation Status and Reveals Alternative Pathway-Activating Mutations in NSCLC
Christoph Arolt(University of Cologne), Axel M. Hillmer(University of Cologne)
Cited by 24
Related Papers
Lymphocyte activation gene 3 (LAG3) protein expression on tumor-infiltrating lymphocytes in aggressive and TP53-mutated salivary gland carcinomas
|Cancer Immunology Immunotherapy|2020|31
Esophageal adenocarcinoma relapse after chemoradiation is dominated by a basal-like subtype
|bioRxiv (Cold Spring Harbor Laboratory)|2025|0